High-Dose versus Standard-Dose Tigecycline Treatment of Secondary Bloodstream Infections Caused by Extensively Drug-Resistant Acinetobacter baumannii: An Observational Cohort Study

References

• NutmanA, GlickR, TemkinE, et al. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clin Microbiol Infect. 2014;20(12):O1028–1034. doi:10.1111/1469-0691.1271624930471
   PubMed Web of Science ®Google Scholar
• RussoA, BassettiM, CeccarelliG, et al. Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study. J Infect. 2019;79(2):130–138. doi:10.1016/j.jinf.2019.05.01731145911
   PubMed Web of Science ®Google Scholar
• NiuT, XiaoT, GuoL, et al. Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem-resistant Acinetobacter baumannii bloodstream infections: cefoperazone-sulbactam associated with resistance and tigecycline increased the mortality. Infect Drug Resist. 2018;11:2021–2030. doi:10.2147/IDR.S16943230464544
   PubMed Web of Science ®Google Scholar
• NiuT, LuoQ, LiY, ZhouY, YuW, XiaoY. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii. Antimicrob Resist Infect Control. 2019;8:52. doi:10.1186/s13756-019-0502-x30886705
   PubMed Web of Science ®Google Scholar
• LiouBH, LeeYT, KuoSC, LiuPY, FungCP. Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure. Antimicrob Agents Chemother. 2015;59(6):3637–3640. doi:10.1128/AAC.04987-1425824230
   PubMed Web of Science ®Google Scholar
• BarbourA, SchmidtS, MaB, et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet. 2009;48(9):575–584. doi:10.2165/11317100-000000000-0000019725592
   PubMed Web of Science ®Google Scholar
• De PascaleG, MontiniL, PennisiM, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18(3):R90. doi:10.1186/cc1385824887101
   PubMed Web of Science ®Google Scholar
• RamirezJ, DartoisN, GandjiniH, YanJL, Korth-BradleyJ, McGovernPC. Randomized Phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57(4):1756–1762. doi:10.1128/AAC.01232-1223357775
   PubMed Web of Science ®Google Scholar
• IbrahimMM, AbuelmattyAM, MohamedGH, et al. Best tigecycline dosing for treatment of infections caused by multidrug-resistant pathogens in critically ill patients with different body weights. Drug Des Devel Ther. 2018;12:4171–4179. doi:10.2147/DDDT.S181834
   Web of Science ®Google Scholar
• BaronJ, CaiS, KleinN, CunhaBA. Once daily high dose tigecycline is optimal: tigecycline PK/PD parameters predict clinical effectiveness. J Clin Med. 2018;7(3):49. doi:10.3390/jcm7030049
   Web of Science ®Google Scholar
• TsachouridouO, GeorgiouA, NanoudisS, et al. Prolonged and high dosage of tigecycline - successful treatment of spondylodiscitis caused by multidrug-resistant Acinetobacter baumannii: a case report. J Med Case Rep. 2017;11(1):186. doi:10.1186/s13256-017-1357-528687078
   PubMedGoogle Scholar
• MylotteJM, TayaraA, GoodnoughS. Epidemiology of bloodstream infection in nursing home residents: evaluation in a large cohort from multiple homes. Clin Infect Dis. 2002;35(12):1484–1490. doi:10.1086/34464912471567
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, Supplement M100-S27. Wayne, Pennsylvania: Clinical and Laboratory Standards Institute. 2017;2017.
   Google Scholar
• PankeyGA. Tigecycline. J Antimicrob Chemother. 2005;56(3):470–480. doi:10.1093/jac/dki24816040625
   PubMed Web of Science ®Google Scholar
• MagiorakosAP, SrinivasanA, CareyRB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x21793988
   PubMed Web of Science ®Google Scholar
• KollefM, MicekS, HamptonN, DohertyJA, KumarA. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54(12):1739–1746. doi:10.1093/cid/cis30522423135
   PubMed Web of Science ®Google Scholar
• MeagherAK, AmbrosePG, GraselaTH, Ellis-GrosseEJ. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis. 2005;52(3):165–171. doi:10.1016/j.diagmicrobio.2005.05.00616105560
   PubMed Web of Science ®Google Scholar
• Sharon SamP, Lisa RussellMD, GuoK. High dose tigecycline for the treatment of multi-drug resistant gram negative urinary tract infections. Open Forum Infect Dis. 2014;1(Suppl 1):S181. doi:10.1093/ofid/ofu052.356
   Google Scholar
• TengSO, YenMY, OuTY, ChenFL, YuFL, LeeWS. Comparison of pneumonia- and non-pneumonia-related Acinetobacter baumannii bacteremia: impact on empiric therapy and antibiotic resistance. J Microbiol Immunol Infect. 2015;48(5):525–530. doi:10.1016/j.jmii.2014.06.01125103719
   PubMedGoogle Scholar
• NgTM, TengCB, LyeDC, ApisarnthanarakA. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol. 2014;35(1):49–55. doi:10.1086/67438724334798
   PubMed Web of Science ®Google Scholar
• MeiH, YangT, WangJ, WangR, CaiY. Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis. J Antimicrob Chemother. 2019;74(12):3423–3431. doi:10.1093/jac/dkz33731377765
   PubMed Web of Science ®Google Scholar
• ChenZ, ShiX. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Medicine (Baltimore). 2018;97(38):e12467. doi:10.1097/MD.000000000001246730235740
   PubMed Web of Science ®Google Scholar
• XiaG, JiangR. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: a retrospective analysis. Medicine (Baltimore). 2020;99(10):e19466. doi:10.1097/MD.000000000001946632150105
   PubMed Web of Science ®Google Scholar
• BaiXR, JiangDC, YanSY. High-dose tigecycline in elderly patients with pneumonia due to multidrug-resistant Acinetobacter baumannii in intensive care unit. Infect Drug Resist. 2020;13:1447–1454. doi:10.2147/IDR.S24935232547113
   PubMed Web of Science ®Google Scholar
• GotfriedMH, HornK, Garrity-RyanL, et al. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother. 2017;61(9):e01135–e01217. doi:10.1128/AAC.01135-17.28696233
   PubMed Web of Science ®Google Scholar
• ZhengY, XuN, PangJ, et al. Colonization with extensively drug-resistant acinetobacter baumannii and prognosis in critically ill patients: an observational cohort study. Front Med. 2021;8:558. doi:10.3389/fmed.2021.667776
   Web of Science ®Google Scholar
• TimsitJF, RuppeE, BarbierF, TabahA, BassettiM. Bloodstream infections in critically ill patients: an expert statement. Intensive Care Med. 2020;46(2):266–284. doi:10.1007/s00134-020-05950-632047941
   PubMed Web of Science ®Google Scholar
• MartínezML, FerrerR, TorrentsE, et al. Impact of source control in patients with severe sepsis and septic shock. Crit Care Med. 2017;45(1):11–19. doi:10.1097/CCM.000000000000201127611975
   PubMed Web of Science ®Google Scholar
• DaviesHE, DaviesRJ, DaviesCW, Group BTSPDG. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010;65(Suppl 2):ii41–ii53. doi:10.1136/thx.2010.13700020696693
   PubMed Web of Science ®Google Scholar
• EckmannC. The importance of source control in the management of severe skin and soft tissue infections. Curr Opin Infect Dis. 2016;29(2):139–144. doi:10.1097/QCO.000000000000024026779777
   PubMed Web of Science ®Google Scholar
• WangH, LiuN, YinM, et al. The epidemiology, antifungal use and risk factors of death in elderly patients with candidemia: a multicentre retrospective study. BMC Infect Dis. 2014;14:609. doi:10.1186/s12879-014-0609-x25420435
   PubMed Web of Science ®Google Scholar
• RhodesA, EvansLE, AlhazzaniW, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304–377.28101605
   PubMed Web of Science ®Google Scholar
• SolomkinJS, MazuskiJE, BradleyJS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133–164. doi:10.1086/64955420034345
   PubMed Web of Science ®Google Scholar